Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.

American journal of clinical pathology - 1 Jun 2008

King Cristi R, Porche-Sorbet Rhonda M, Gage Brian F, Ridker Paul M, Renaud Yannick, Phillips Michael S, Eby Charles

Abstract excerpt

Initiation of warfarin therapy is associated with bleeding owing to its narrow therapeutic window and unpredictable therapeutic dose. Pharmacogenetic-based dosing algorithms can improve accuracy of initial warfarin dosing but require rapid genotyping for cytochrome P-450 2C9 (CYP2C9) *2 and *3 single nucleotide polymorphisms (SNPs) and a vitamin K epoxide reductase (VKORC1) SNP. We evaluated 4 commercial systems:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Mixed Function Oxygenases

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 18480003
DOI: 10.1309/1E34UAPR06PJ6HML

Genes

CYP2C9
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.PMID 18480003Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.Semantic proximity Read ↗

Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Warfarin pharmacogenetics.Semantic proximity Read ↗

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Semantic proximity Read ↗

New allele-specific real-time PCR system for warfarin dose genotyping equipped with an automatic interpretative function that allows rapid, accurate, and user-friendly reporting in clinical laboratories.Semantic proximity Read ↗

Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.